Budget 2026: Structured funding framework will deepen innovation, R&D: Satish Reddy
K Satish Reddy, Chairman, Dr Reddy’s Laboratories
The expectations of the Pharma sector from the upcoming Union Budget 2026 centre on the creation of a structured funding framework to deepen innovation and R&D across the country, according to K Satish Reddy, Chairman, Dr Reddy’s Laboratories.
“This would enable the companies to translate advanced research into complex, high-value therapies while improving patient access.’’ Reddy said in a statement.
The pharma sector is poised to play a pivotal role in realising the vision of Viksit Bharat and its ambition of becoming a $500 billion industry by 2047, he added.
“India’s pharmaceutical sector has earned global trust through its scale, quality and affordability. As the industry undertakes a strategic shift from volume-led expansion to value-driven growth, closer alignment between science, policy and industry will be critical to advancing innovation across the value chain,’’ Dr Reddy’s Chairman said.
Equally important was the need to build a supportive ecosystem that ensures sustained financing for pharmaceutical innovation. Reforms in regulation, particularly to encourage greater participation from start-ups, would be a significant step forward in strengthening India’s life sciences innovation landscape, he added.
Published on January 19, 2026
